What’s New from the 2016 ESMO Clinical Guidelines

Update to the “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors”

National Comprehensive Cancer Network NSCLC Guideline Updates for 2016: Non-Small Cell Lung Cancer

HER2 Mutations Present Unique Challenges in NSCLC

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

Palliative Care Benefits Vary Depending on Providers, Timing

From the Editor: Looking Back on 2022

Increasing Evidence Demonstrates the Usefulness of ctDNA

CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says

Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?